In this podcast, Dr. Truchetet discusses her work on the role of innate lymphoid cells in the fibrotic processes in systemic sclerosis (SSc) patients. The group of Dr. Truchetet found that ILC2 are crucial mediators of skin fibrosis in SSc and that combined treatment of patients with TGFb inhibitors and IL-10 might be an attractive new therapeutic approach in SSc.

Read the full paper on the ARD website: https://ard.bmj.com/content/80/12/1594